Open AccessDisparities in clinical features and outcomes of peripartum cardiomyopathy in high versus low prevalent regions in Nigeria
Author(s) -
Karaye Kamilu M.,
Ishaq Naser A.,
Sai'du Hadiza,
Balarabe Sulaiman A.,
Ahmed Bashir G.,
Adamu Umar G.,
Mohammed Idris Y.,
Oboirien Isa,
Umuerri Ejiroghene M.,
Mankwe Abaram C.,
Shidali Vincent Y.,
DodiyiManuel Sotonye,
Njoku Paschal,
Olunuga Taiwo,
Josephs Veronica,
Mbakwem Amam C.,
Ogah Okechukwu S.,
Tukur Jamilu,
Okeahialam Basil,
Stewart Simon,
Henein Michael,
Sliwa Karen
Publication year - 2021
Publication title -
esc heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.787
H-Index - 25
ISSN - 2055-5822
DOI - 10.1002/ehf2.13463
Subject(s) - peripartum cardiomyopathy , medicine , asymptomatic , heart failure , cardiomyopathy , statistical significance , selenium deficiency , prospective cohort study , post hoc analysis , clinical significance , pediatrics , catalase , oxidative stress , glutathione peroxidase
Aims The prospective, multicentre Peripartum Cardiomyopathy in Nigeria (PEACE) registry originally demonstrated a high prevalence of peripartum cardiomyopathy (PPCM) among patients originating from Kano, North‐West Nigeria. In a post hoc analysis, we sought to determine if this phenomenon was characterized by a differential case profile and outcome among PPCM cases originating elsewhere. Methods and results Overall, 199 (81.6%) of a total 244 PPCM patients were recruited from three sites in Kano, compared with 45 patients (18.4%) from 11 widely dispersed centres across Nigeria. Presence and extent of ventricular myocardial remodelling during follow‐up, relative to baseline status, were assessed by echocardiography. During median 17 months follow‐up, Kano patients demonstrated significantly better myocardial reverse remodelling than patients from other sites. Overall, 50.6% of patients from Kano versus 28.6% from other regions were asymptomatic ( P = 0.029) at study completion, with an accompanying difference in all‐cause mortality (17.6% vs. 22.2% respectively, P = 0.523) not reaching statistical significance. Alternatively, 135/191 (84.9%) of Kano patients had selenium deficiency (<70 μg/L), and 46/135 (34.1%) of them received oral selenium supplementation. Critically, those that received selenium supplementation demonstrated better survival (6.5% vs. 21.2%; P = 0.025), but the supplement did not have significant impact on myocardial remodelling. Conclusions This study has shown important non‐racial regional disparities in the clinical features and outcomes of PPCM patients in Nigeria, that might partly be explained by selenium supplementation.